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Abstract
Background: Trials increasingly experience problems in recruiting participants. Understanding the causes of poor
recruitment is critical to developing solutions. We interviewed people who had declined a trial of an innovative
psychological therapy for depression (REFRAMED) about their response to the trial invitation, in order to understand
their decision and identify ways to improve recruitment.
Methods: Of 214 people who declined the trial, 35 (16 %) gave permission to be contacted about a qualitative
study to explore their decision. Analysis of transcripts of semi-structured interviews was informed by grounded
theory.
Results: We interviewed 20 informants: 14 women and six men, aged 18 to 77 years. Many interviewees had prior
experience of research participation and positive views of the trial. Interviewees’ decision making resembled a four-
stage sequential process; in each stage they either decided not to participate in the trial or progressed to the next
stage. In stage 1, interviewees assessed the invitation in the context of their experiences and attitudes; we term
those who opted out at this stage ‘prior decliners’ as they had an established position of declining trials. In stage 2,
interviewees assessed their own eligibility; those who judged themselves ineligible and opted out at this stage are
termed ‘self-excluders’. In stage 3, interviewees assessed their need for the trial therapy and potential to benefit; we
term those who decided they did not need the trial therapy and opted out at this stage ‘treatment decliners’. In
stage 4, interviewees deliberated the benefits and costs of trial participation; those who opted out after judging
that disadvantages outweighed advantages are termed ‘trial decliners’. Across all stages, most individuals declined
because they judged themselves ineligible or not in need of the trial therapy. While ‘prior decliners’ are unlikely to
respond to any trial recruitment initiative, the factors leading others to decline are amenable to amelioration as
they do not arise from a rejection of trials or a personal stance.
Conclusions: To improve recruitment in similar trials, the most successful interventions are likely to address patients’
assessments of their eligibility and their potential to benefit from the trial treatment, rather than reducing trial burden.
Trial registration: International Standard Randomised Controlled Trial Number: ISRCTN85784627. Registration date 10
August 2011.
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Background
Randomised trials are strongly recommended for evaluat-
ing interventions, yet recruitment of participants is an in-
creasing problem [1–3]. In developed countries, there
have been considerable efforts to improve recruitment
through legislation and infrastructure [4–6]. Recent re-
ports in the United Kingdom (UK) suggest that more
people than ever are being approached to participate in
trials [6]; however the proportion of people who enrol is
small and recruitment remains a problem, with between
45 % and 80 % of trials failing to meet recruitment targets
[2, 7]. The difficulties may be even more pronounced
when enrolling patients with depression, with many exam-
ples of trial failure due to poor recruitment [8, 9]. The
challenges stem from sources including: the stigma of
mental illness; poor identification of mental disorders by
clinicians; diagnoses which adversely affect patients’ ability
and motivation to participate in research; and mistrust
[10, 11]. Consequences of poor recruitment include
increased costs, reduction in statistical power and contin-
ued use of interventions that are ineffective or harmful to
patients [12, 13].
There is a dearth of evidence-based interventions for
improving recruitment into trials, leading to calls for the
development of ‘a science of recruitment’ [1, 14]. Recruit-
ment is now a methodological research priority for trials
units in the UK [15], and systematic reviews have identi-
fied an urgent need for robustly evaluated interventions,
particularly those tested in the real world [16, 17].
The Medical Research Council (MRC) Complex
Interventions Framework provides a useful basis for de-
veloping and evaluating interventions to improve recruit-
ment [18, 19]. Qualitative research has an important role
to play in the development of interventions [20–22]. To
improve recruitment, it is important that this develop-
ment work is informed by the perspectives of people who
decline trials. However, our meta-synthesis of factors
affecting recruitment into depression trials [23] found that
only one of the 15 studies included decliners [24]. The
remaining studies all focused on the perspectives of staff,
or of patients successfully recruited. Furthermore, all of
the studies focused on respondents’ reported reasons for
their decision, but did not explore in detail their accounts
of what happened when they received the invitation to
join a trial. This may have elicited idealised justifications
and failed to take into account deliberation, an important
aspect of decision making identified by the ‘deliberation
and determination’ framework [25, 26]. Understanding
responses to the invitation to join a trial and how the deci-
sion to decline is reached may assist trialists to enhance
recruitment by designing interventions to address short-
comings. By exploring this important gap in our under-
standing, we aimed to shed light on what has been termed
a ‘blind spot in the literature’ on recruitment [27].
We therefore explored interviewees’ accounts of what
they did and what happened when they received the trial
invitation. Rather than simply asking for reasons why
they declined trial participation, which might elicit idea-
lised justifications rather than deliberations and reasons,
we explored informants’ accounts of how they reached
their decisions and the factors that affected them.
Methods
Setting: the REFRAMED trial
This qualitative study explored interviewees’ responses to
receiving an invitation to participate in the REFRAMED
trial (REFRActory depression - Mechanisms and Efficacy of
Dialectical Behaviour Therapy) [28]. REFRAMED evaluated
the effectiveness of Radically Open Dialectical Behavioural
Therapy (RO-DBT) [29] for treatment-resistant depression.
It recruited trial participants through general practices and
mental health services in Dorset and Hampshire in England
and Gwynedd in North Wales. Those eligible were: aged
over 18 years; had a current diagnosis of depression; and
had not responded to antidepressants. All invited individ-
uals received a ‘summary participant information leaflet’
(Additional file 1) and those who were interested took part
in full eligibility assessments. Eligible individuals who con-
sented were randomised to RO-DBT in addition to usual
care and antidepressant medication, or to usual care and
antidepressant medication. RO-DBT comprised 29 weekly
individual therapy sessions lasting 50 minutes and 27 group
skills sessions lasting 2.5 hours. While some components of
RO-DBT are common to all behaviour therapies, RO-DBT
uniquely targets social-signalling deficits, focuses on chan-
ging internal experience (for example emotion dysregula-
tion, cognitive distortions and traumatic memories) and
also teaches clients how to express emotions appropriate to
context and use non-verbal social-signalling strategies
known to enhance social connectedness. REFRAMED par-
ticipants were assessed four times over 18 months – at
baseline and after 7, 12 and 18 months; in addition RO-
DBT participants completed monthly questionnaires over
18 months.
Qualitative study
The qualitative study was informed by an epistemo-
logical standpoint of pragmatism, a perspective that em-
braces methodological pluralism and is increasingly used
in health services research to inform the development
and evaluation of interventions that are transferable and
usable in real life [30, 31]. Pragmatism focuses on ‘what
works’ and on generating solutions to existing problems
by identifying and integrating effective strategies to build
on the strengths and reduce the inherent flaws of each
[32, 33]. Our pragmatic approach enabled us to use dif-
ferent methods of sampling, data collection and analysis
to address our research aims, including techniques from
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grounded theory [34]. Grounded theory aims to generate
theories of social phenomena grounded in systematic
analysis of data and is particularly appropriate for
explaining social processes. We offered individuals who
had declined the REFRAMED trial the choice between
being interviewed by telephone or email. These options
were informed by: advice from two patient and carer en-
gagement groups – the UK Clinical Research Network
Mental Health Service User Research Panel (SURP) and
Primary care Research In Manchester Engagement
Resource (PRIMER); advice from trialists who had
worked with similar groups; literature suggesting that
decliners would be reluctant to take part in face-to-face
interviews [24]; and evidence that well-planned tele-
phone and email interviews can gather the same data as
interviews face to face [24, 35] and promote access to
‘isolated, geographically dispersed or stigmatised groups
who are often overlooked or ignored’ [36, 37].
Sampling and recruitment
Most of the 1867 patients approached for REFRAMED
were identified from electronic health records in general
practices and community mental health teams by
searching for patients diagnosed with depression who
were receiving repeat prescriptions of antidepressants.
Of the rest, a few referred themselves, but most were
referred to REFRAMED by their general practitioners
(GPs), care coordinators and psychiatrists. We could not
access those who declined their clinicians’ invitations so
our sampling for the qualitative study focused on the
214 patients who responded to postal invitations from
general practices and community mental health teams
by returning reply slips to decline REFRAMED, in par-
ticular the 35 who expressed interest in participating in
the interviews and provided contact details.
We initially sampled 12 interviewees for maximum
variation [38] in the following characteristics: age, gen-
der and geographic location. In line with the principles
of grounded theory, we then sampled theoretically [39],
using information provided on decliners’ reply slips. We
invited eight interviewees who gave different reasons for
declining and who we therefore felt were ‘deviant’ or
could provide accounts that would help us to develop
our analyses further [34]. We continued sampling until
we achieved data saturation; that is until no new themes
emerged.
Data collection
One of us, AH-M, a health services researcher undertaking
a PhD with training in qualitative interviewing, contacted
those who expressed interest – by telephone or email ac-
cording to their preferences – to discuss the qualitative
study. Having had no prior contact with interviewees, she
explained that she was linked to the REFRAMED team but
independent of both them and patients’ clinical teams, and
sought consent from potential interviewees. Arrangements
were made to conduct telephone or email interviews at a
later date with those who consented. Audio interviews were
recorded and professionally transcribed in an ‘efficient ver-
batim’ style, that is by transcribing content but not pauses
or hesitations. AH-M checked transcripts for accuracy and
pseudonymised them.
Recruitment to REFRAMED took place between March
2012 and May 2015 and the qualitative interviews took
place between August 2013 and January 2015 – within
3 months of interviewees declining to participate in
REFRAMED so as to minimise recall bias. To allow full
exploration of topics, interviews were conversational and
responsive to participants. To ensure consistency across
interviews, questions followed a topic guide (Additional
file 2), which was piloted and based on relevant literature
and consultation with SURP and PRIMER, our patient
and carer engagement groups. Interviews initially explored
participants’ recollection of and thoughts about: being in-
vited into the trial; making the decision to decline; under-
standing the research and trial interventions; and talking
therapies, in particular RO-DBT. Interviews focused on
the period when respondents first received the invitation
into the REFRAMED trial, and asked them to describe in
detail what they did, who they talked to, and what they
thought. We made field notes during interviews and
modified the topic guide in response to early interviews.
To minimise interviewee burden, transcripts were not
returned to respondents, nor were they asked to provide
feedback on findings.
Data analysis
Analysis was interpretive and drew on constant compari-
son with grounded theory [34]. The iterative analysis
process was led by AH-M who read and reread tran-
scripts to develop preliminary codes to identify themes
and theoretical categories [40], which we gradually de-
veloped into a conceptual framework. Coding was com-
bined with a holistic consideration of transcripts to
retain the context of participants’ accounts and identify
and interpret aspects that participants were silent about
or did not emphasise relative to the accounts of other
participants, or which did not fit the rest of their ac-
count. In discussion with BY and PB, AH-M continually
reviewed emerging themes and categories in the light of
new data, modifying these to ensure they fitted the data
whilst accounting for deviations. Some categories and
themes arose from inductive analysis, while others drew
more deductively on literature from our systematic
review [23]. This flow from data to literature, and back
to the data, refined the codes and the developing theoret-
ical constructs [41]. The multi-disciplinary team devel-
oped the analysis and ensured its ‘trustworthiness’ [42, 43]
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in a process of investigator triangulation. Analysis was
assisted by NVivo 10.
To illustrate our interpretations we include selected
quotations from our data. These are broadly representa-
tive of the key themes, whilst also reflecting a range of
views. Quotation labels indicate participants’ age, gender,
identification number and stage at which they declined;
for example ‘67F01S03’ indicates a 67-year-old female
who was our first participant and declined at stage 3.
Text within square brackets [] indicates clarifications
that we have inserted; ellipses ‘…’ indicate pauses by re-
spondents; and ellipses within square brackets […] indi-
cate omitted text.
Results
Participant characteristics
Of the 35 patients initially expressing interest, two de-
clined to be interviewed when contacted and eight did not
respond to our attempts to contact them. The remaining
five were not interviewed as we had reached theoretical
saturation. We undertook 20 interviews with 14 females
and six males – 18 by telephone, one by email and one by
both telephone and email. Apart from the interviewee and
the researcher, no other persons were present during the
interviews. Telephone interviews lasted between 16 and
76 minutes with a mean of 30 minutes. The email inter-
view took place over the course of one week; and for the
combined interview the telephone interview occurred
first, followed by one day’s email correspondence. The
mean age of the 20 who participated in the qualitative
study was 57 years; the mean age of the 252 who partici-
pated in REFRAMED was 45 years and that of the 214
who declined was 50 years. Of the 20 interviewees, 18 de-
scribed themselves as ‘white British’, one as ‘white other’
and another as ‘Asian British’. Ten were retired, six were
unemployed, three were employed full time and one was a
full-time student. Ten interviewees had prior experience
of being invited to participate in a trial. Table 1 lists the
characteristics of interviewees.
Overview of informants’ decision making
Ten interviewees read the trial invitation with experience
of having made trial participation decisions in the past.
Our analysis of their accounts of their response to receiv-
ing the trial invitation indicated that they passed through
up to four sequential stages in making the participation
decision: (1) assessing the nature of the invitation; (2)
assessing their own eligibility; (3) assessing their own need
for trial therapy and potential to benefit; and (4) compar-
ing the risks with the rewards of participation. While all
informants engaged in stage 1, two described opting out
of the trial at this stage without further deliberation. Of
those progressing to stage 2, nine declined at this stage,
seven at stage 3, and two progressed to stage 4 before
finally declining. Thus while two progressed through all
four stages of this process, the majority reached their deci-
sion earlier. However, the content of informants’ delibera-
tions did not always reflect this sequential order, for
example some considered the potential to benefit from
the therapy (stage 3) before assessing their eligibility (stage
2). In reporting their accounts, we characterise different
‘types’ of decision makers to distinguish the decisions that
interviewees made at each stage of the process of respond-
ing to the REFRAMED invitation.
Stage 1: assessing the nature of the invitation
In the REFRAMED trial GPs and mental health teams
sent invitation letters to potential participants without
prior notice. Informants generally reported opening the
letter without delay and reading it with the trial response
form. Some reported that they briefly glanced through
the accompanying REFRAMED summary leaflet or did
not read it, while others described reading the leaflet in
detail. With one exception, informants reported that:
they approved of being sent the trial invitation; the letter
format was appropriate; and being invited in this way
was good because it enabled them to make decisions in
their own time:
‘The letter is a good idea…I mean if they sign you up
you have to decide very quickly and you don’t have
time to chew over the information, so having a letter
makes sense, you can sit and think about it and decide
what to do’. (66M12S2)
The exception was an interviewee widowed one year
before receiving the trial invitation. She reported that,
given her personal circumstances, she would have
expected her GP to have removed her name from the list
of patients to be sent the invitation. However, she
acknowledged that for people experiencing ‘normal
depression’, being sent such an invitation was not only
appropriate, but would actually be positive:
‘It probably is a good thing really, if I’m honest. I
mean, it’s the only way you get to know things, isn’t
it?… Like, say, I’d got some illness, I suppose it’s the
only way you’re going to find out things isn’t it, what
tablets I’m on, whether they work and all that sort of
thing. I think perhaps if I’d been depressed normally,
like, I mean, a lot of people are, aren’t they, and
they’re on depression tablets for a while. I can
understand that’. (70F08S2)
The other interviewees expressed positive views about
research and the trial specifically, particularly the need
to improve health services and advance knowledge
through such endeavours:
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‘Without research no-one would ever get anywhere,
would they? So even if it didn’t help me, it would still
help, you know, others wouldn’t it?’ (44F09S3)
Many respondents reported that they supported
REFRAMED’s aim to evaluate a new treatment for depres-
sion, and were comforted to know ‘that somebody was
doing something about it’ (67F01S3).
For ten informants this was not the first time they had
been invited by letter to participate in research. Of these,
eight reported having accepted at least one invitation.
Three of these were trials of psychological therapy for de-
pression; one a psychological experiment including mood
assessment; two studied bowel cancer; one respiratory ill-
ness; and one vision. Being sent such letters was seen as a
necessary part of the research process, regardless of
whether the invitation was declined or accepted. Crucially,
interviewees felt able to make whatever decision felt right
for them, including declining, so did not mind being
invited:
‘I didn’t mind actually because I know that the
[general practice] was very into research and I believe
that the surgery itself was one of the best in the
country for research. I had been sent them on, I think,
about bowel cancer and, I can’t remember, two or
three other things and I must admit that my reaction
was just the same’. (74F05S1)
This interviewee, whom we categorised as a ‘prior de-
cliner’, reported that REFRAMED was one of several tri-
als that she had declined owing to concerns about
confidentiality. The other ‘prior decliner’, who reported
having declined all invitations, was the oldest of our in-
terviewees, and cited her advanced age as the reason for
not accepting trial invitations:
‘I’m 77…when you get to this age, you realise that you
just take every day at a time, and I don’t want
anything that I haven’t got to have, because I’ve had
two hip replacements, I’ve had an operation on my
back, and to be quite honest, as I say, I don’t want
anything that isn’t necessary. I don’t think that at this
stage in my life, [trials] apply to me, really’. (77F11S1)
Thus these two ‘prior decliners’ had made prior deci-
sions not to participate in trials for different reasons –
confidentiality and being ‘too old’. Yet both accounts
centred on their personal circumstances and their pol-
icy of declining all trial invitations, and both declined
very quickly and with little deliberation, as they had
established a precedent.
Table 1 Characteristics of study participants
Participant number Age Site Gender Highest educational qualification
1 67 England F Secondary school
2 18 Wales F Secondary school
3 67 Wales M Secondary school
4 54 England F University degree or higher
5 74 England F Secondary school
6 59 England M Secondary school
7 62 Wales M University degree or higher
8 70 England F Secondary school
9 44 England F Secondary school
10 73 England F Secondary school
11 77 England F University degree or higher
12 66 Wales M University degree or higher
13 63 England M Secondary school
14 69 England F Secondary school
15 40 England F University degree or higher
16 46 Wales F University degree or higher
17 61 England F Secondary school
18 50 England F Secondary school
19 38 England M University degree or higher
20 45 Wales F University degree or higher
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In contrast most interviewees reported making decisions
that took account of the features of each trial presented to
them. The remaining 18 interviewees, including eight who
had previously participated in research, made decisions
specific to the REFRAMED trial. These interviewees
approached the REFRAMED decision with positive atti-
tudes despite perceiving mixed outcomes from that previ-
ous research:
‘It was excellent… And it’s been the greatest help I’ve
ever had actually. I mean, 40 years I’ve been suffering
with depression but this came at a latter stage of my
life obviously and I took it’. (62M07S3)
Whilst others found it to be of less direct benefit:
‘I think the person that was doing [the study] got more
benefit than I did. I was just helping that person out,
which I didn’t mind doing’. (54F04S2)
Interviewees with no experience of trials often
recounted experiences of close family members who had
made decisions to enrol in trials, described supporting
their family members’ decisions, and displayed positive
opinions and detailed knowledge of those trials:
‘One of my husband’s problems is that he now has
end-stage kidney failure, and has had for the last
8 years. When he was initially diagnosed with chronic
renal failure [pharmaceutical company] were instigating
a massive worldwide research into statins and the effect
on renal failure. My husband agreed to enter into that
and I appreciate that they basically give people either a
placebo or the real drug[…]And it was perfectly obvious
from my husband’s statins – prior to taking the drug, his
cholesterol was six-something and 3 months after it had
gone down to two. So it was pretty obvious that he didn’t
have the placebo.’ (74F05S1)
Thus interviewees were universally positive about the
trial, even the ‘prior decliners’.
Stage 2: determining own eligibility
With the exception of prior decliners, all respondents
described engaging with trial eligibility on reading the
letter. Interviewees described: the trial eligibility criteria;
their perceptions of their eligibility for the trial; and their
identification by clinical teams who sent them the trial
invitation. Their accounts revealed differences in the
interpretation of the diagnosis and management of
depression. Nine interviewees described using the trial
information and eligibility criteria to decide how to
respond to the invitation in light of their personal cir-
cumstances. They fell into two broad ‘self-excluding’
categories: those who judged that they were ineligible
because they were not taking antidepressants prescribed
by their clinical teams (though they may have been
considered eligible by those teams); and those who de-
scribed themselves as ‘not depressed enough’.
The trial eligibility criteria required patients to have
a current diagnosis of major depressive disorder, to
have been prescribed antidepressants, and not to have
responded to these within the current episode. All
participants in this qualitative study had been identi-
fied by their clinical teams as matching these criteria.
Six interviewees reported that, when invited into
REFRAMED, they had never taken their prescribed
antidepressants, or soon stopped doing so, without
informing their doctors. They had decided not to par-
ticipate in the trial, perceiving that they were ineli-
gible for the trial, rather than rejecting the trial itself.
One reported that doctors had prescribed him antide-
pressants on several occasions, but he had always re-
fused to take them, because he felt strongly that he
did not need them to manage his mood, and worried
about the effects of long-term antidepressant use on
his health:
‘I really do believe going onto antidepressants,
particularly long-term, is not a good thing’. (62M07S3)
Other interviewees, who had initially taken their pre-
scribed antidepressants, reported that they had stopped
taking them without consulting their doctors when they
felt they no longer needed medication, or they did not
‘like taking them’ (59M06S2). Several interviewees re-
ported side effects from the antidepressants, which they
had managed by stopping their medication. Another
interviewee described asking her GP to stop antidepres-
sants immediately as her mood had improved, but her
GP had insisted on reducing the dose gradually:
‘She wanted me to wind it down…she made me have
one more lot’. (70F08S2)
Thus respondents pointed to differences between
themselves and their treating clinicians in perceptions of
the diagnosis of depression and its management. Some
managed these differences by doing what felt right, often
without consulting their doctors.
Other interviewees had been taking their antide-
pressants but considered themselves ineligible because
their depression was not severe enough to meet the
inclusion criteria in the trial invitation. These respon-
dents reported that: they were ‘not very depressed’;
they were on maintenance doses of antidepressants;
their antidepressants were for comorbid conditions
like anxiety; their depression was not the main
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problem; or their mood had improved as a result of
taking antidepressants:
‘The thing was I’d been on tablets but they seemed to
have worked’. (69F14S2)
Some interviewees reported that, to be of use to the
trial, they needed to be much more unwell than they
were:
‘I didn’t think you’d learn anything from me’.
(73F10S2)
Thus respondents and their clinical teams differed in
their interpretation of eligibility for the trial. The fluidity
of the diagnosis of depression may have allowed these
differing interpretations that led to interviewees exclud-
ing themselves from the trial. The imprecision of the ini-
tial screening process via electronic health records may
have given further scope for interviewees to exclude
themselves and not progress to the full assessment of
eligibility (by a member of the REFRAMED team). As
one participant commented:
‘Our GP practice must have sent the letter to everyone
with the word “depression” in their records rather than
going for the precise criteria’. (66M12S2)
In summary the term ‘self-excluders’ describes the
nine respondents who labelled themselves as ineligible
after reading the initial invitation. Typically they did not
deliberate on the decision, but soon returned the ‘opt-
out’ form to the trial team.
Stage 3: assessing own need for trial therapy and potential
to benefit
Other participants focused their decision making on the
trial therapy. This is distinct from stage 2, in that infor-
mants who progressed to stage 3 considered the trial’s
potential to benefit their health, rather than their poten-
tial to benefit the trial. They viewed the trial as offering
an adjunct to current treatment, and focused their deci-
sion making on whether they were likely to benefit from
the trial therapy. These seven interviewees, whom we
term ‘treatment decliners’ indicated that once they had
assessed that they did not need the trial therapy they de-
cided to decline:
‘I don’t need it. If I did need it, then yes, it’s good’.
(67F01S3)
These informants saw the trial invitation as offering
help to manage their depression. Whilst they acknowl-
edged that they were depressed, some described their
depression as not as severe as others’, and therefore in
less need of help:
‘I don’t think that I’m that ill enough to warrant
anything a great deal anyway, if you know what I
mean. There are people far more depressed than what
I am and need more help than I do’. (67F01S3)
Other interviewees compared their present state with
past episodes of depression. Several claimed they were
better able to ‘cope’ with their present state than with
past episodes, and therefore did not feel in need of the
trial therapy:
‘I thought, well I’m not actually, I mean, I’m bumping
along on a low dose of antidepressants, I’ve retired
from work, things are going reasonably’. (66M12S2)
Despite the trial invitation stressing randomisation, all
interviewees assumed they would receive the trial ther-
apy. They made their decision by focusing on what
would happen should they receive the trial therapy, ra-
ther than on the uncertainty of receiving one of two pos-
sible allocations. Some did go on to reflect on the
difficult situation that could arise if a hypothetical de-
pressed person focused their decision on their need for
the treatment but was randomised to ‘usual care’. Infor-
mants emphasised how help was often lacking for people
with depression and people were sometimes ‘desperate’
for treatment. In this context, one informant talked of
how it was ‘almost cruel’ to offer people the chance to
enrol into a trial but then not provide the trial treat-
ment, and advised that people could experience feelings
of frustration and rejection:
‘People are sometimes desperate for something new or
different that will get rid of the pain…for people with
mental health issues where feelings of suicide pop up
now and again it can be almost cruel if you were not
to be chosen[…]Feelings of distress and frustration can
be ever so amplified. You can feel so disheartened’.
(46F16S4)
Similarly, another interviewee who had participated
in a trial of psychological therapy for depression
(which he had completed not long before being in-
vited into REFRAMED) described how he had en-
rolled in the previous trial because he had wanted
help for his depression; and he had declined to par-
ticipate in REFRAMED because his depression was
much improved as a consequence of receiving the ac-
tive psychological intervention in the previous trial.
He recognised there was a chance he might not re-
ceive the psychological intervention in the previous
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trial; however he had enrolled with the clear aim of
being assigned to psychological therapy:
‘That was my target. I aimed to get the assessments
right, so they would put me on the [trial therapy],
because I wanted something to help me. No question of
it, that was my goal. I never thought any different’.
(62M07S3)
Thus there was also a belief that the randomisation
outcome depended on the baseline assessments.
This and other accounts saw trials as providing access
to potentially life-prolonging and life-enhancing treat-
ment not otherwise available. The perception was that
trials are fulfilling health needs, rather than providing an
impartial mode of resolving clinical uncertainty. Thus
not to receive the trial treatment was problematic for
people seeking novel healthcare where few other options
were available. In declining REFRAMED, however, pa-
tients did not feel they ‘needed’ the trial therapy to man-
age their depression. However, it is clear from these
accounts that, if interviewees had felt they needed the
therapy, they would have considered enrolling in the
trial with the aim of accessing the trial therapy to man-
age their depression.
Stage 4: deliberating burdens and benefits of trial
participation
The remaining two interviewees deliberated about the
costs and benefits of trial participation, but only after de-
ciding that they could benefit from the trial therapy. We
describe them as ‘trial decliners’. They considered the bur-
den of the research procedures and the commitment
required to participate. Personal circumstances, like caring
and work responsibilities, were key considerations along-
side the distance and time from home to therapy and
other inconveniences caused by participation.
Interviewees expressed this in terms of comparing bur-
dens and rewards. The burdens arose from the time
commitment, both to therapy and research follow-up;
one focused on the number and length of therapy ses-
sions, regarded as time-consuming and ‘intense’, whilst
the other focused on the follow-up period of 18 months:
‘The long-term commitment was a nightmare for me
as I was looking for work, going for interviews and not
really knowing what I would be doing or where I would
be over the next 18 months’. (46F16S4)
This debate was important only to the two people who
judged that they were eligible and could benefit from the
trial therapy – the ‘trial decliners’. Most interviewees de-
cided to opt out of the trial earlier in the deliberation
process and did not consider inconvenience as a primary
reason for not participating; for them eligibility and need
for the trial therapy trumped inconvenience.
Discussion
Summary of main findings
The 20 interviewees had positive views of research and
of the aims of the REFRAMED trial in particular. Many
had experience of research participation. The interviews
enabled us to identify four stages in the process of decid-
ing whether or not to participate in the REFRAMED
trial. At each stage some respondents concluded their
deliberation and opted out. In stage 1 the ‘prior
decliners’ opted out, who have an established position of
declining trial participation, stemming from personal cir-
cumstances, for example viewing themselves as ‘too old’.
In stage 2, the ‘self-excluders’ who use the trial eligibility
criteria to declare themselves ineligible opted out; they
see their illness and its management differently from the
clinical team who invited them to participate. In stage 3
the ‘treatment decliners’ opted out, who perceive that
they may be eligible, but focus on their health needs and
decide that they do not need the trial therapy. In stage 4
the ‘trial decliners’ opted out, who perceive that they
may be eligible and in need of the trial therapy, but
focus on the burden of trial participation and decide that
that outweighs potential benefits.
Strengths and limitations
Our study adds to the very sparse literature on non-
participation in randomised trials. To our knowledge
this is the first qualitative study to explore explicitly how
decisions to decline invitations to mental health trials
were made and to present the results in a conceptual
framework of decision making.
There are gender and age differences in the presentation
and diagnosis of depression [44, 45], and most primary
care depression trials enrol many more females than males
[46]. Our sample of 14 (70 %) women and six (30 %) men,
with ages ranging from 18 to 77 years, reflects the demo-
graphics of depression trials and is a strength of this
study.
We used telephone and e-mail interview methods and
it is possible that, compared with face-to-face interviews,
these may compromise rapport, probing and interpret-
ation of interview responses [47]. However, using these
methods enabled us to interview a hard-to-reach group
who otherwise may not have engaged [48, 49] and to
achieve a degree of anonymity which arguably helped in-
terviewees to disclose their experiences.
It is possible that interviewees present themselves as
rational deliberators in studies of this sort, because that
is what they perceive is expected of them. We minimised
this risk by asking interviewees simply to report what
happened when they received the trial invitation, rather
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than to provide detailed elaborations of their decision
making process and some – the ‘prior decliners’ who
had previously made similar decisions to decline other
trials – clearly reported that they made the decision with
little deliberation. Some interviews occurred months
after the initial refusal. While some respondents had dif-
ficulty recalling details, most recalled the invitation and
decision process in detail and provided vivid accounts.
As in all studies of volunteers, informants selected
themselves. However, participants represented only 16 %
of decliners, which may limit the transferability of our
findings. Interviewees expressed very positive views of
research, presumably because, like other studies of non-
participation, we could not access those averse to research.
However, we doubt whether research-averse individuals
could help to enhance recruitment, as they would not re-
spond to recruitment interventions.
Patients who declined after being directly approached
by clinicians to participate in REFRAMED also could not
contribute to this study. Such patients may have offered
different views, particularly around eligibility and self-
exclusion issues, since clinicians were perhaps more likely
to approach those whom they were confident would meet
the trial eligibility criteria.
Whilst we undertook purposive sampling, the small
numbers of patients who responded limited the scope of
that. Despite this we did reach data saturation with those
interviewed. Finally, the novel treatment in REFRAMED
was aimed at patients with refractory depression and
was particularly intense, so findings may not be transfer-
able to other depression trials.
Comparison with existing literature
Our meta-synthesis [23] shows that patients’ decisions to
enter depression trials depend on: their health at the time
of the invitation; their attitudes towards the research and
trial interventions; and the demands of the trial. Our con-
ceptual framework describes how decisions to participate
require judgment between ‘risk and reward’. This qualita-
tive study supports that meta-synthesis by showing that in
making their decisions, respondents balanced their
current health and whether they would benefit from the
trial therapy against the burden of participating in the
therapy including travel and time. In planning this study,
we sought to contribute to existing knowledge. For ex-
ample, we focused on patients under-represented in the
previous literature by exploring how those who opted out
of REFRAMED made their decisions.
Our findings reflect the wider decision-making litera-
ture, in particular the ‘deliberation and determination’
framework [25]. This framework differentiates between
the pre-decisional process of deliberation, the act of deter-
mination and post-decisional outcomes. Our findings and
the stages appear to match this process of ‘deliberation’, in
which the person considers the invitation in light of their
eligibility, experiences and need; and determination, which
is the act of choosing to not participate. Our classification
of individuals as ‘prior decliners’, ‘self-excluders’, ‘treatment
decliners’ and ‘trial decliners’ appears to reflect the ‘deter-
mination’ phase of the deliberation and determination
framework.
Our findings in this subgroup contrast with the gen-
eral literature which suggests that altruism is a major
reason for research participation [50–52]. Our respon-
dents initially assessed their eligibility for the trial, then
focused on their need for the trial therapy, and their po-
tential to benefit. There is evidence that perceived ineli-
gibility can lead people with depression to decline trial
participation [24], and that patients participating in trials
focus on the therapy under review and consider personal
benefits from it [53–57]. The term ‘conditional altruism’
describes willingness to help others that inclines people
to participate in trials, but does not clinch trial participa-
tion unless they judge that this will benefit them person-
ally [57]. Whilst interviewees appeared to understand
that randomisation meant that those who enrol might
not receive the trial intervention, their accounts revealed
the perception of randomisation in treatment trials as
fundamentally unfair, even ‘cruel’ in cases where people
may be seeking treatment through trial participation.
Thus our group of decliners demonstrated similar attitudes
to those who enrol to gain therapeutic benefit from trial
participation. A relevant concept is the therapeutic miscon-
ception – a blurring of research and treatment, and thus a
threat to understanding the trial and its risks [58–61].
There is some evidence that patients who decline par-
ticipation often misunderstand the nature of the re-
search [62, 63]. More pertinent to our interviewees,
however, may be the concept of the therapeutic mis-
estimation, which misunderstands the likelihood of risks
and benefits rather than the general purpose of trials [64].
We found that interviewees had positive attitudes to re-
search and the trial. This contrasts with some literature
on non-participation which reports that decliners are less
supportive of research [65–67]. Despite not participating,
our interviewees generally did not mind being invited and
felt free not to participate. There is evidence that most pa-
tients with mental health problems approve of psychiatric
research [50], and that non-participation does not reflect
objection to research in principle [63, 68]. Patients who
opt out of trials have reported that they do not object to
being asked to participate, nor do they feel any pressure to
do so [69].
Implications for recruitment practice and future research
Our findings have several implications for trial recruit-
ment and ethical and methodological research on it.
First it is important to recognise that those whom we
Hughes-Morley et al. Trials  (2016) 17:494 Page 9 of 13
term ‘prior decliners’ are unlikely to respond to any re-
cruitment initiative as they have an established stance of
declining all trial invitations. However, other factors
leading patients to opt out of trials may be open to
amelioration as they do not arise from a rejection of tri-
als or personal stances of declining such invitations.
To improve responses to postal invitations in similar
trials, the most successful interventions are likely to ad-
dress patients’ assessments of their eligibility and their
potential to benefit from the trial treatment, rather than
reducing the burden of that treatment. Trialists can in-
fluence patients’ assessments of eligibility by exploring
methods of:
(a)managing electronic patient records to estimate
eligibility more precisely;
(b)influencing patients’ own assessment of eligibility
and their judgments of their potential to benefit
from the trial treatment; and
(c)drafting trial invitations, for example to minimise
the risk of excluding themselves as ineligible.
The wording of invitations could be evaluated to
examine the effect of conveying broader criteria on the
numbers initially expressing interest, and ultimately en-
rolled. It is unclear whether ‘self-excluders’ make the same
decisions that the trial team would, and whether the trial
team would also have excluded them as not meeting the
inclusion criteria. Thus trialists could evaluate a trial invi-
tation letter which lists the precise inclusion and exclusion
criteria against a comparator invitation which lists only
the condition under investigation (e.g. ‘depression’), to es-
timate how many people initially respond in each arm,
how many are excluded by the trial team and how many
are ultimately enrolled. While eligibility issues are com-
plex, there may be a case for accepting the risk of attract-
ing more patients who turn out to be ineligible rather
than being too restrictive. However, our findings caution
against raising patients’ expectations in a way that would
be unrealistic.
We know from our study that most patients focus on
their need for the trial therapy when deciding whether
to participate, whatever their final decision. Thus Miller
and Brody [70] and Schlichting [71] have argued for
trials to serve health needs, by abandoning the trad-
itional commitment to clinical equipoise and conducting
research ‘with therapeutic intent’. This approach replaces
the ethical framework of equipoise with that of non-
exploitation, so as to achieve the goals of patients, clini-
cians and researchers [71]. Though detailed examination
of this ethical dilemma is beyond the scope of this study,
trialists should know that our respondents effectively sup-
ported this radical proposal. The implication of accepting
the principle of research ‘with therapeutic intent’ is that
trials should aim, not only for a favourable benefit-risk ra-
tio for society, but also to avoid an unfavourable benefit-
risk ratio for each trial participant [72, 73]. Our qualitative
study suggests that trialists should prospectively monitor
patients’ expectations of their trials and use that to inform
design and delivery. Better, patient-centred explanations of
the potential benefits of trial treatments may help [74].
Engaging service users and members of the public in
the design and conduct of trials alongside qualitative
research may be the key to this [75]. For example,
qualitative research could explore patient treatment
preferences [76, 77]. Thus a priority for future research
is the presentation and provision of accurate and effect-
ive trial information in which patients and the public
play a seminal role [78]. Retrospective but timely feed-
back from patients who opt out of trials can assess the
acceptability of the treatment being evaluated [24].
Early inclusion of such feedback into trial recruitment
procedures can increase participation rates [79]. How-
ever, all such interventions require robust evaluation,
ideally through embedded randomised trials.
Conclusions
We have studied how patients invited into a randomised
trial in mental health decided not to participate. They
opted out in a sequence of four stages: first, the ‘prior de-
cliners’ who have an established position of declining trial
participation; second, the ‘self-excluders’ who judge that
they are ineligible; third, the ‘treatment decliners’ who de-
cide that they do not need the trial therapy; and finally the
‘trial decliners’ who decide that the burden of trial partici-
pation outweighs potential benefits. These findings have
positive implications for improving trial recruitment,
because trialists can address most of these issues.
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